Deborah A Marshall1, Karen V MacDonald2, Sebastian Heidenreich3,4, Taila Hartley5, Francois P Bernier6, Meredith K Gillespie5, Brenda McInnes6, A Micheil Innes6, Christine M Armour5, Kym M Boycott5. 1. Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada. Damarsha@ucalgary.ca. 2. Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada. 3. Health Economics Research Unit, University of Aberdeen, Aberdeen, Scotland. 4. Evidera, Inc., London, UK. 5. Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada. 6. Department of Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Abstract
PURPOSE: Exome sequencing (ES) can rapidly identify disease-causing variants responsible for rare, single-gene diseases, and potentially reduce the duration of the diagnostic odyssey. Our study examines how parents and families value ES. METHODS: We developed a discrete choice experiment (DCE) survey that was administered to parents of children with rare diseases. The DCE included 14 choice tasks with 6 attributes and 3 alternatives. A valuation-space model was used to estimate willingness to pay, willingness to wait for test results, and minimum acceptable chance of a diagnosis for changes in each attribute. RESULTS: There were n = 319 respondents of whom 89% reported their child had genetic testing, and 66% reported their child had a diagnosis. Twenty-six percent reported that their child had been offered ES. Parents were willing to pay CAD$6590 (US$4943), wait 5.2 years to obtain diagnostic test results, and accept a reduction of 3.1% in the chance of a diagnosis for ES compared with operative procedures. CONCLUSION: Timely access to ES could reduce the diagnostic odyssey and associated costs. Before ES is incorporated routinely into care for patients with rare diseases in Canada and more broadly, there must be a clear understanding of its value to patients and families.
PURPOSE: Exome sequencing (ES) can rapidly identify disease-causing variants responsible for rare, single-gene diseases, and potentially reduce the duration of the diagnostic odyssey. Our study examines how parents and families value ES. METHODS: We developed a discrete choice experiment (DCE) survey that was administered to parents of children with rare diseases. The DCE included 14 choice tasks with 6 attributes and 3 alternatives. A valuation-space model was used to estimate willingness to pay, willingness to wait for test results, and minimum acceptable chance of a diagnosis for changes in each attribute. RESULTS: There were n = 319 respondents of whom 89% reported their child had genetic testing, and 66% reported their child had a diagnosis. Twenty-six percent reported that their child had been offered ES. Parents were willing to pay CAD$6590 (US$4943), wait 5.2 years to obtain diagnostic test results, and accept a reduction of 3.1% in the chance of a diagnosis for ES compared with operative procedures. CONCLUSION: Timely access to ES could reduce the diagnostic odyssey and associated costs. Before ES is incorporated routinely into care for patients with rare diseases in Canada and more broadly, there must be a clear understanding of its value to patients and families.
Authors: Suzana Karim; Benjamin M Craig; Caroline Vass; Catharina G M Groothuis-Oudshoorn Journal: Pharmacoeconomics Date: 2022-08-12 Impact factor: 4.558
Authors: James Clayton Parker; Sneha Rangu; Katheryn Lynn Grand; Elizabeth Joyce Bhoj; Leslie Castelo-Soccio; Sarah E Sheppard Journal: Am J Med Genet A Date: 2021-01-27 Impact factor: 2.802
Authors: Emily G Miller; Amanda L Woodward; Grace Flinchum; Jennifer L Young; Holly K Tabor; Meghan C Halley Journal: Genet Med Date: 2021-07-19 Impact factor: 8.864
Authors: Aarushi Gupta; Joseph A Cafazzo; Maarten J IJzerman; Joost F Swart; Sebastiaan Vastert; Nico M Wulffraat; Susanne Benseler; Deborah Marshall; Rae Yeung; Marinka Twilt Journal: J Med Internet Res Date: 2021-12-24 Impact factor: 5.428
Authors: Samantha Pollard; Deirdre Weymann; Jessica Dunne; Fatemeh Mayanloo; John Buckell; James Buchanan; Sarah Wordsworth; Jan M Friedman; Sylvia Stockler-Ipsiroglu; Nick Dragojlovic; Alison M Elliott; Mark Harrison; Larry D Lynd; Dean A Regier Journal: Eur J Hum Genet Date: 2021-04-26 Impact factor: 4.246
Authors: Christie P Thomas; Margaret E Freese; Agnes Ounda; Jennifer G Jetton; Myrl Holida; Lama Noureddine; Richard J Smith Journal: Genet Med Date: 2020-03-17 Impact factor: 8.822